Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Acute Myeloid Leukemia
8%
Adenocarcinoma
9%
Adjuvant Therapy
10%
Adolescence
8%
Adverse Event
28%
Antineoplastic Activity
9%
Arm
24%
B-Cell Chronic Lymphocytic Leukemia
15%
Bevacizumab
10%
Biological Marker
23%
Biopsy Technique
13%
Brain Metastasis
13%
Breast Cancer
51%
CA-125
7%
Cancer
42%
Cancer Cell
8%
Carcinoma
7%
Cervical Cancer
18%
Chemoradiotherapy
10%
Chemotherapy
54%
Cisplatin
12%
Clear Cell Renal Cell Carcinoma
8%
Clinical Trial
33%
Colon Carcinoma
12%
Colorectal Carcinoma
18%
COVID-19
12%
Cystectomy
9%
Cytokine
9%
Disease Exacerbation
7%
Disease Free Survival
11%
Diseases
100%
Drug Megadose
20%
Epidermal Growth Factor Receptor
10%
Gastroesophageal Reflux
9%
Genetics
16%
Glioblastoma
18%
Gynecological Oncology
18%
Hazard Ratio
14%
Head and Neck Cancer
8%
Health Care Cost
12%
Hematopoietic Cell
8%
Histology
9%
Immune Response
11%
Immunotherapy
39%
Infection
13%
Intensity Modulated Radiation Therapy
13%
Interleukin 2
16%
Ipilimumab
8%
Krukenberg Tumor
13%
Lobectomy
8%
Lung
14%
Lung Cancer
26%
Lymph Duct
15%
Lymph Node
23%
Lymphocyte
8%
Magnetic Resonance Imaging
9%
Malignant Neoplasm
65%
Median Follow Up
14%
Melanoma
74%
Melanoma Skin Cancer
11%
Metastatic Carcinoma
26%
Metastatic Melanoma
22%
Morbidity
16%
Neck
12%
Neoplasm
86%
Nivolumab
10%
Non Small Cell Lung Cancer
32%
Odds Ratio
12%
Oncology
30%
Oral
7%
Ovarian Cancer
24%
Overall Survival
60%
Pelvis
8%
Pembrolizumab
11%
Phase II Trials
14%
Placebo
11%
Platinum
12%
Pneumonectomy
8%
Primary Tumor
10%
Prognostic Factor
8%
Progression Free Survival
32%
Prostate Cancer
17%
Quality of Life
18%
Radiation Therapy
41%
Recurrent Disease
40%
Retroperitoneal Lymph Node Dissection
21%
Sentinel Lymph Node
18%
Sentinel Node
16%
Solid Malignant Neoplasm
19%
Sphincter
7%
Squamous Cell Carcinoma
8%
Surgeon
20%
Surgery
11%
Survival Rate
11%
T Cell
20%
Targeted Therapy
10%
Transsphenoidal Surgery
8%
Tumor
52%
Tumor Cell
9%
Uterine Cancer
12%
Immunology and Microbiology
Adaptive Immune System
8%
Agonist
13%
Antigen
19%
Antigen Specificity
8%
Antineoplastic Activity
5%
Arm
8%
Autoimmunity
5%
B Cell
10%
Bevacizumab
6%
Blood Plasma
8%
Cancer Cell
12%
Cancer Immunotherapy
13%
CD134
5%
CD3 Antigen
6%
CD4
12%
CD8
12%
Cell Line
6%
Cell Transplantation
7%
Chemokine
6%
Circulating Tumor Cell
7%
Colon
6%
Colorectal Carcinoma
12%
COVID-19
7%
CTLA-4
8%
Cyclophosphamide
5%
Cytokine
18%
Cytotoxic T Cell
6%
Cytotoxic T-Cell
33%
Dendritic Cell
11%
Disease Free Survival
6%
Drug Megadose
9%
Gene Expression
7%
Granulocyte Macrophage Colony-Stimulating Factor
7%
Hematopoietic Cell
8%
Immune Response
28%
Immune System
6%
Immunocompetent Cell
10%
Immunogenicity
5%
Immunotherapy
56%
In Vitro
18%
Infection
15%
Infectious Disease
14%
Inflammation
8%
Interferon Type I
11%
Interleukin 2
19%
Interleukin 4
5%
Intravenous Immunoglobulin
6%
Kinase
6%
Lung
29%
Lymph Node
13%
Lymphocyte
13%
Macrophage
12%
Melanoma Cell
10%
Memory T Cell
5%
Monoclonal Antibody
11%
Monocyte
5%
Myeloid
10%
Natural Killer Cell
8%
Neck
11%
Neoantigen
9%
Overall Survival
32%
Pembrolizumab
7%
Peptides
13%
Phosphotransferase
6%
Programmed Cell Death
6%
Programmed Death-Ligand 1
7%
Progression Free Survival
14%
Regulatory T Cell
11%
Reperfusion
6%
Ribonucleic Acid
5%
Squamous Cell
10%
T Cell
81%
T Cell Receptor
14%
T-Helper Cell
17%
Trastuzumab
8%
Tumor Antigen
16%
Tumor Cell
20%
Tumor Immunity
7%
Tumor Necrosis Factor
8%
Tumor Vaccine
11%
Tumor-Infiltrating Lymphocytes
10%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
6%
Adverse Event
29%
Antigen
6%
Antitumor Activity
11%
Bevacizumab
13%
Biological Marker
19%
Brain Metastasis
8%
Breast Cancer
20%
Carboplatin
9%
Carotene
6%
Castration Resistant Prostate Cancer
5%
Chemotherapy Regimens
37%
Chronic Lymphatic Leukemia
11%
Cisplatin
10%
Clinical Trial
29%
Colorectal Carcinoma
9%
Cyclophosphamide
5%
Cytokine
9%
Diarrhea
6%
Disease Exacerbation
5%
Diseases
50%
Doxorubicin
5%
Endometrium Cancer
5%
Epidermal Growth Factor Receptor
7%
Fluorouracil
6%
Gemcitabine
5%
Glioblastoma
11%
Immunotherapy
31%
Infection
5%
Interferon
6%
Interleukin 2
10%
Ipilimumab
9%
Lenvatinib
5%
Lung Cancer
16%
Malignant Neoplasm
52%
Maximum Tolerated Dose
8%
Melanoma
36%
Metastatic Melanoma
8%
Monoclonal Antibody
8%
Monotherapy
14%
Neoplasm
51%
Neutropenia
5%
Nivolumab
9%
Non Small Cell Lung Cancer
23%
Nonhodgkin Lymphoma
5%
Ovary Cancer
16%
Ovary Carcinoma
5%
Overall Survival
26%
Paclitaxel
9%
Pembrolizumab
14%
Pharmacodynamics
5%
Pharmacokinetics
15%
Phase I Trials
8%
Phase II Trials
18%
Placebo
11%
Platinum
10%
Progression Free Survival
24%
Prostate Cancer
16%
Receptor
6%
Recurrent Disease
12%
Remission
6%
Renal Cell Carcinoma
7%
Retinol
9%
Rituximab
6%
Small Cell Lung Cancer
6%
Solid Malignant Neoplasm
31%
Tolerability
9%
Trastuzumab
5%
Tumor Growth
5%
Urea Cycle Disorder
5%
Uterine Cervix Cancer
12%
Vasculotropin
5%